Suying Lü

2.4k total citations
95 papers, 1.3k citations indexed

About

Suying Lü is a scholar working on Oncology, Molecular Biology and Neurology. According to data from OpenAlex, Suying Lü has authored 95 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 32 papers in Molecular Biology and 32 papers in Neurology. Recurrent topics in Suying Lü's work include Neuroblastoma Research and Treatments (25 papers), Lymphoma Diagnosis and Treatment (17 papers) and Lung Cancer Research Studies (9 papers). Suying Lü is often cited by papers focused on Neuroblastoma Research and Treatments (25 papers), Lymphoma Diagnosis and Treatment (17 papers) and Lung Cancer Research Studies (9 papers). Suying Lü collaborates with scholars based in China, Canada and United States. Suying Lü's co-authors include Michael C. Archer, Àngel Pellicer, Ramón Mangues, Fei Zou, Marcos Malumbres, Jia Zhu, Junting Huang, W. Fraser Symmans, Feifei Sun and Alan Medline and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Suying Lü

80 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suying Lü China 20 684 318 236 107 96 95 1.3k
Mi Hou Sweden 23 1.1k 1.6× 255 0.8× 166 0.7× 101 0.9× 114 1.2× 38 2.1k
Dong Zhang China 25 973 1.4× 289 0.9× 432 1.8× 182 1.7× 64 0.7× 74 1.9k
Jeremy D. Henson Australia 20 1.8k 2.6× 204 0.6× 163 0.7× 72 0.7× 38 0.4× 31 2.4k
D. Morrison United States 20 1.0k 1.5× 231 0.7× 188 0.8× 123 1.1× 70 0.7× 31 1.8k
James Denvir United States 22 774 1.1× 286 0.9× 269 1.1× 101 0.9× 48 0.5× 65 1.4k
Long Cheng China 20 728 1.1× 147 0.5× 213 0.9× 125 1.2× 110 1.1× 60 1.2k
Amar Bennasroune France 18 510 0.7× 257 0.8× 155 0.7× 183 1.7× 40 0.4× 36 1.2k
Amy Au Australia 16 1.3k 1.9× 339 1.1× 346 1.5× 133 1.2× 65 0.7× 23 1.9k
Xuedong Wang China 18 568 0.8× 356 1.1× 300 1.3× 124 1.2× 47 0.5× 50 1.3k
Takahiro Ueda Japan 22 1.2k 1.8× 378 1.2× 440 1.9× 185 1.7× 114 1.2× 81 2.3k

Countries citing papers authored by Suying Lü

Since Specialization
Citations

This map shows the geographic impact of Suying Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suying Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suying Lü more than expected).

Fields of papers citing papers by Suying Lü

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suying Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suying Lü. The network helps show where Suying Lü may publish in the future.

Co-authorship network of co-authors of Suying Lü

This figure shows the co-authorship network connecting the top 25 collaborators of Suying Lü. A scholar is included among the top collaborators of Suying Lü based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suying Lü. Suying Lü is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cheng, Yao, Liqiang Wu, Suying Lü, et al.. (2025). 336P: Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis. Journal of Thoracic Oncology. 20(3). S203–S204.
3.
Mao, Lei, Mengzhen Li, Juan Wang, et al.. (2025). Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: a real-world study in China. Frontiers in Immunology. 16. 1608844–1608844.
4.
Chen, Danian, Suying Lü, Katherine Huang, et al.. (2025). Cell cycle duration determines oncogenic transformation capacity. Nature. 641(8065). 1309–1318. 3 indexed citations
5.
Shen, Yifan, Zhen Li, Suying Lü, et al.. (2024). 640P Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation. Annals of Oncology. 35. S1642–S1643. 1 indexed citations
6.
Lü, Suying, et al.. (2024). Current therapeutic landscape and resistance mechanisms to larotrectinib. Cancer Biology and Medicine. 20(12). 967–971. 2 indexed citations
7.
Que, Yi, Juan Wang, Feifei Sun, et al.. (2023). Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study. Signal Transduction and Targeted Therapy. 8(1). 392–392. 5 indexed citations
8.
Chen, Tingting, Juan Wang, Feifei Sun, et al.. (2023). Long‐term follow‐up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities. Cancer Medicine. 12(8). 9409–9419. 1 indexed citations
9.
Li, Mengzhen, Yang Hu, Yanjie Xu, et al.. (2023). The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma. International Journal of Oncology. 64(2). 8 indexed citations
10.
Ortín-Martínez, Arturo, En Leh Samuel Tsai, Lacrimioara Comanita, et al.. (2021). Photoreceptor nanotubes mediate the in vivo exchange of intracellular material. The EMBO Journal. 40(22). e107264–e107264. 43 indexed citations
11.
Wang, Juan, Lian Zhang, Yi Que, et al.. (2021). Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor. Frontiers in Oncology. 11. 721564–721564. 4 indexed citations
12.
Zhu, Xiaoqin, Wei Li, Jia Zhu, et al.. (2021). Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma. Leukemia & lymphoma. 62(10). 2374–2382. 4 indexed citations
13.
Lü, Suying, Xiaoqin Zhu, Wei Li, et al.. (2021). Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients. Frontiers in Oncology. 11. 598226–598226. 10 indexed citations
14.
Sun, Chengtao, Mengzhen Li, Yanfen Feng, et al.. (2020). <p>MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma</p>. OncoTargets and Therapy. Volume 13. 10475–10487. 13 indexed citations
15.
Qian, Dong, Kailin Chen, Hui‐Lan Rao, et al.. (2015). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clinical Cancer Research. 21(21). 4881–4891. 55 indexed citations
16.
Li, Pengfei, Zijun Zhen, Zhuowei Liu, et al.. (2014). Effect of excision extension of primary tumors on local control and survival of stage IV neuroblastoma. Clinical Oncology and Cancer Research. 41(24). 1568–1572. 1 indexed citations
17.
Wu, Jin-Ya, Xiaotao Jiang, Yunxia Jiang, et al.. (2010). Effects of polymerase, template dilution and cycle number on PCR based 16 S rRNA diversity analysis using the deep sequencing method. BMC Microbiology. 10(1). 255–255. 96 indexed citations
18.
Kotsopoulos, Joanne, Alan Medline, Richard Renlund, et al.. (2005). Effects of dietary folate on the development and progression of mammary tumors in rats †. Carcinogenesis. 26(9). 1603–1612. 48 indexed citations
19.
20.
Lü, Suying, et al.. (2001). Susceptibility of lean and obese Zucker rats to tumorigenesis induced by N- methyl- N- nitrosourea. Cancer Letters. 162(2). 155–160. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mi Hou Breakdown of academic impact, for papers by Dong Zhang Breakdown of academic impact, for papers by Jeremy D. Henson Breakdown of academic impact, for papers by D. Morrison Breakdown of academic impact, for papers by James Denvir Breakdown of academic impact, for papers by Long Cheng Breakdown of academic impact, for papers by Amar Bennasroune Breakdown of academic impact, for papers by Amy Au Breakdown of academic impact, for papers by Xuedong Wang Breakdown of academic impact, for papers by Takahiro Ueda
Rankless by CCL
2026